Kornimate/medical-research-clean huggingface dataset:
concentration-controlled therapy of mycophenolate mofetil (mmf) in proliferative lupus nephritis

Conditions: Lupus Nephritis

Summary: to evaluate therapeutic response to mmf treatment in patients with international society of nephrology/renal pathology society (isn/rps) class iii or iv lupus nephritis. mycophenolic acid levels at 1-hour post dose will be monitored monthly up to 6 months.


Eligibility criteria:
inclusion criteria: * age 16-60 years. * ability and willingness to provide written informed consent (or to obtain consent from parent guardian where applicable) and to comply with the schedule of protocol requirements * diagnosis of sle according to acr criteria. at least 4 criteria must have been present for the diagnosis of sle. the 4 criteria do not have to be present at the time of screening * active lupus nephritis defined as follows: biopsy proven (within 16 weeks prior to screening) isn class iii or iv (a or a/c) not include iii(c) iv(c) and vi (\>90% chronic irreversible scarring) exclusion criteria: relates to sle * severe renal impairment as defined by calculated creatinine clearance or mdrd-gfr \ 50 ml/min in the 12 weeks prior to screening) * history of serious disease or complication in any organ system that not appropriate to treatment immunosuppressive drug groups. related to treatment * previous of any mycophenolate groups in the 3 months prior to screening. * treatment with more than 2 g cyclophosphamide in the last 6 months period prior to screening. * receipt of more than 3 g iv pulse methylprednisolone within the last 3 months prior to screening. * receipt of prednisolone dose \> 30 mg/day for longer than 30 days within last 3 months prior to screening. related to general health * pregnancy or breast feeding mothers. * evidence of significant uncontrolled concomitant disease in any organ system not related to sle. * history of cancer, including solid tumors, hematological malignancies and carcinoma. * history of serious recurrent or chronic infection. * evidence of current abuse of drugs or alcohol. related to laboratory findings * neutrophile \< 1,500/mm3, hb \< 7g/l, platelet \< 50,000/mm3 (except active sle) * positive hbsag or anti-hcv or anti-hiv.

Keywords: trough level therapeutic drug monitoring mycophenolate mofetil mycophenolic acid lupus nephritis
effectiveness of diabetes prevention education program on diabetes prevention among prediabetes population in nepal

Conditions: Prediabetic State

Summary: background: the prediabetes population is a high risk group for developing diabetes and is also associated with a higher risk of micro- and macrovascular complications. prevalence of prediabetes is also increasing in nepal (10.3%). therefore, appropriate strategies should be developed to detect prediabetes and prevent its complications. early detection of prediabetes offers opportunity for intervention to prevent diabetes either by reverting into normoglycemia or stabilizing blood glucose levels. even a small shift in weight loss and reduction of glycated haemoglobin (hba1c) (i.e., a change in hba1c of 0.5%) can be significant in reducing cardiometabolic risk. therefore, we propose to develop a culturally tailored diabetes prevention education program (dipep) for nepal and implement this program among a prediabetes population with the aim to prevent diabetes. aims: primary aim of the research is to test the effectiveness of a diabetes prevention education program (dipep) in lowering glycated haemoglobin (hba1c %) among a pre-diabetes population in nepal. our secondary aims are to test the effectiveness of dipep in improving health literacy in diabetes, reducing weight, improving healthy diet and physical activity. we also aim to explore acceptability and usability of dipep among a prediabetes population and perception of adoption and sustainability of dipep in the health sector of nepal. significance: prevention of diabetes, especially type 2 diabetes mellitus (t2dm) is proven, possible and powerful. it is more cost effective than spending huge money in treatment and usual care. it requires modification of dietary and exercise behavior, which are efficacious, safe, and cost-effective measures. therefore, a culturally tailored dipep intervention program for nepal will serve as an additional reference resource for the non-communicable disease division of ministry of health to develop and implement national diabetes prevention program if they decide such program is important for nepal. it will be helpful to achieve non-communicable disease target 3.4 of the sustainable development goal by nepal government's ministry of health. additionally, it will be beneficial for the prediabetes population who could have developed t2dm in short span of time if they had been undiagnosed and unconsidered. therefore, the main significance of the study is it will provide knowledge and environment to prevent diabetes at their community level.


Eligibility criteria:
inclusion criteria: * permanent residents of dhulikhel municipality or lalitpur metropolitan city (patan) * indian diabetes risk score 60 or higher * prediabetes: glycated haemoglobin (hba1c) 5.7-6.4 % * random blood sugar ≥ 140 to ≤ 250 mg/dl exclusion criteria: * type 1 diabetes (self-report) * type 2 diabetes * under medication * hba1c criteria (≥ 6.5 %) * currently pregnant * critically ill patients

Keywords: patient education nepal diabetes prevention
a clinical trial to evaluate the detection of atrial fibrillation for an one day versus more than or equal to eight days using memo patch plus in individuals aged ≥ 75 years, or those at high risk of stroke

Conditions: Atrial Fibrillation/Flutter in Patients With High Risk of Stroke

Summary: the purpose of this study is to evaluate the benefits in the atrial fibrillation detection rate of the continuous ecg monitoring group for more than 8 days by contrasting with one-day ecg monitoring using memo patch plus in 1000 patients with atrial fibrillation-related symptoms in the high risk group of stroke. the participant is allocated randomly to one-day ecg monitoring group or the continuous ecg monitoring group for more than 8 days in ratio of 1:1, only if the participant provides informed consent and eligible for all the inclusion/exclusion criteria. the investigator confirms the results of memo patch plus monitoring at 1 month from the date of memo patch plus attachment. the participation of the subject is terminated on the 1 year from the date of memo patch plus attachment. on that day, investigator evaluates incidence of the event associated with atrial fibrillation, the event is included ischemic stroke/transient ischemic accident, hemorrhagic stroke, systemic embolism, etc.


Eligibility criteria:
\[inclusion criteria\] a participant will be eligible for inclusion in the study if the participant: 1. has provided documented informed consent for the study. 2. is adult at least 19 years of age on the day of providing documented informed consent 3. is the high risk group for stroke, i.e. adult at least 75 years of age or cha2ds2-vasc score more than 2 4. is life expectancy more than 6 months 5. has no atrial fibrillation or atrial flutter as a result of 12-lead ecg 6. has symptoms associated with atrial fibrillation \*symptoms associated with atrial fibrillation: palpitation, dizziness, dyspnea, syncope, stroke/transient ischemic accident, systemic embolism etc. \[exclusion criteria\] the participant must be excluded from the study if the participant: 1. has had prior history of atrial fibrillation or atrial flutter 2. has received prior or ongoing anticoagulant or antiplatelet therapy 3. has inserted pacemaker or defibrillator that can diagnose atrial fibrillation or atrial flutter 4. has plan of carotid endarterectomy or inserting stent\* within 90 days on the day of providing document informed consent \*stent insertion: means when stent-related interventions have been performed on the carotid arteyr or coronary arteries.
the study of breast mri screening and proton magnetic resonance spectroscopy

Conditions: Breast Diseases

Summary: to delineate if the chemical composition (lipid and water) in the presumably normal breast of the high risk women is different from those of the low risk group.

the researchers would like to investigate and compare the chemical composition in the normal breast between high risk women and general population.

Eligibility criteria:
inclusion criteria: * women without breast symptoms (without family history of breast cancer; or with at least first-degree relative of breast cancer) with negative mammography and ultrasound result in recent 3 months or contralateral normal breasts from women with newly diagnosed unilateral breast cancer * 25-75 years old. exclusion criteria: * renal function impairment * past history of anaphylactoid reaction to mri contrast media (gd-dtpa) * pregnant or lactating women * medication of hrt or oral pills in recent 6 months * past history of surgery of the breast (either side) * past history of breast cancer * with breast implant or silicone injection * past history of cardiac surgery, mechanical valve replacement, aneurismal clip, endotracheal tube or tracheostomy tube, any metallic implants.

Keywords: breast diseases magnetic resonance spectroscopy
the efficacy and safety of hrs8179 in severe cerebral edema following large hemispheric infarction

Conditions: Severe Cerebral Edema Following Large Hemispheric Infarction

Summary: the study is being conducted to evaluate the efficacy, and safety of hrs8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere


Eligibility criteria:
inclusion criteria: 1. fully understand and voluntarily participate in this trial, and sign the informed consent form (the informed consent form can be signed voluntarily by the participant or their legal representative); 2. a clinical diagnosis of acute ischemic stroke in the middle cerebral artery (mca) territory; 3. national institutes of health stroke scale (nihss) ≥ 10 at screening; 4. a large hemispheric infarction defined as: lesion volume of 80 to 160 cm3 on magnetic resonance imaging (mri) diffusion-weighted imaging (dwi), or computed tomography perfusion (ctp). 5. the time from onset to treatment must be ≤ 10 hours; if the onset time is unknown, treatment must be initiated within 10 hours after the time last known normal. exclusion criteria: 1. theparticipant is likely to withdraw the supportive treatment on the first day; 2. there is evidence indicating a concurrent infarction in the contralateral hemisphere sufficiently serious to affect functional outcome. 3. there are clinical signs of brain herniation; ct/mri indicates a midline shift of \>2 mm; ct/mri indicates cerebral hemorrhage;
perceptions of weather risks and climate beliefs among the hong kong general public

Conditions: Weather Risk Perception

Summary: background: local abnormal heat events may be used as proxies for communicating the health impacts of climate change when people physically feel the effects to reduce the psychological distance of climate change and improve public engagement with climate and weather risk. however, there are concerns that this strategy may be more effective for climate believers, and that it may somewhat compromise the scientific precision because it may lead to erroneous beliefs that climate change is merely characterized by temperature rises or extreme heat but ignore other extreme weather events such as flood and extreme cold, and that cold spells are interpreted as evidence of no climate change. none of these potential effects and concerns has been tested. aims: this proposed study is aimed to explore patterns of climate beliefs and their influences on perceptions of heat-related risks and responses to heat health warnings in the general public of hong kong; (2) test the preliminary effects of a revised heat health warning (rhhw) that incorporates information about the health impacts of climate change into existing heat health warning on perceived heat-related risk and climate beliefs. design and subjects: this will be a mix-methods study comprising in-depth qualitative interviews, a population-based cohort survey and a pilot randomized control trial (rct). subjects will be the general hong kong chinese adults aged ≥18 years. main outcome measures: latent class analysis will be conducted to examine patterns of climate beliefs while structural equation modelling to test the relationships among climate beliefs, perceived heat-related risks and behavioural responses to heat warnings. qualitative data will be analysed using thematic content analysis while the effect of rhhw will be tested using t-test and linear regression models.


Eligibility criteria:
inclusion criteria: * participants should own a mobile phone and be able to read chinese. exclusion criteria: * participants with no mobile phone or cannot understand chinese will be excluded.
treatment of cfs and fibromyalgia with hrg 80 red ginseng

Conditions: Fibromyalgia; CFS

Summary: will a unique form of ginseng be clinically helpful in those with chronic fatigue syndrome and fibromyalgia?

ginseng has been shown in earlier studies to help fatigue in a number of conditions. but because of overharvesting, most ginseng is no longer have optimal levels of the active ginsenosides. a new technique has been developed to restore the level of active ginseng components those found in the wild ginseng used in earlier studies. this is available in a form called hrg 80 red ginseng. the study is an open pilot study to explore whether this treatment would be helpful for improving clinical function and symptomatology in chronic fatigue syndrome and fibromyalgia. current clinical experience is suggesting that it may be.

Eligibility criteria:
inclusion criteria: 1. be diagnosed with cfs and/or fibromyalgia 2. live in the united states 3 - be over 18 years of age exclusion criteria: * pregnancy

Keywords: ginseng
tailored h. pylori eradication based on clarithromycin resistance

Conditions: Helicobacter Pylori Infection; Antibiotic Resistant Strain

Summary: the investigators investigated the point mutations in the 23s rrna genes of patients infected with clarithromycin-resistant h. pylori and compared the h. pylori eradication rates based on the identified clinically significant point mutations.

sequencing-based detection of point mutations identified four mutations that were considered clinically significant (a2142g, a2142c, a2143g, a2143c), while all the other mutations were considered clinically insignificant. participants who did not have point mutations related to clarithromycin resistance and/or had clinically insignificant point mutations were treated with pac (proton pump inhibitor, amoxicillin, clarithromycin) for 7 days, while participants with clinically significant point mutations were treated with pam (proton pump inhibitor, amoxicillin, metronidazole) for 7 days. h. pylori eradication rates were compared between the two groups.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of helicobacter pylori infection exclusion criteria: * h. pylori eradication therapy within 1 year, * antibiotics within 4 weeks, * surgery for gastric cancer * malignant tumors other than gastric cancer * end-stage renal disease * liver cirrhosis, * pregnancy
cerebrolysin neural repair therapy in children with traumatic brain injury and cerebral palsy

Conditions: Cerebral Palsy Children; Children With Traumatic Brain Injury; Mental Handicap; Delayed Speech Development

Summary: cerebral palsy (cp) is the most frequent cause of motor handicap among children. the economic burden of cp in usa includes $1.18 billion in direct medical costs, $1.05 billion in direct non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of $11.5 billion or $921,000 average cost per person. associated disabilities as mental retardation, delayed speech development add psychological burden of the disease on the family as well as economic burden. mental retardation is the major problem in children with cerebral palsy. improving mental development will have a positive effect on quality of life for the child and his family. treating associated impairments (mental retardation) with cerebrolysin will improve mental development and quality of life, and will decrease the economic burden in children with cerebral palsy.


Eligibility criteria:
inclusion criteria: * cerebral palsy with mental retardation * severe perinatal brain insult exclusion criteria: 1. severe growth retardation 2. gastrostomy tube feeding 3. intractable seizures. 4. severe motor handicap and deformities from long standing spasticity. 5. congenital malformations. 6. suspected inborn error of metabolism. 7. suspected inherited neurologic disease. 8. children with auditory and visual impairments. 9. care giver's refusal to participate in the study.

Keywords: cerebral palsy children cerebrolysin sleep questionnaire quality of life bayley iii scale
intravenous paricalcitol in chronic hemodialysis patients

Conditions: Endstage Renal Disease; Secondary Hyperparathyroidism

Summary: this study aims to provide intravenous paritcalcitol treatment for the sick and poor hemodialysis patients with severe secondary hyperparathyroidism (shpt) resistant to existing vitamin d analogs therapy or with hypercalcemia precluding the use of existing vitamin d analogs. the study aims to evaluate the effect of paricalcitol on control of shpt, biochemical parameters of chronic kidney disease-mineral bone disease, cardiac parameters, vascular calcification and stiffness parameters and nutrition status in patients receiving chronic hemodialysis treatment.

this is a 2-year single-arm intervention study of which intravenous paricalcitol will be provided as a second-line treatment to 30 chronic hemodialysis patients with severe shpt (defined as intact parathyroid hormone \[ipth\] ≥ 800pg/ml) resistant to existing vitamin d analogs treatment (including rocaltrol and alfacalcidol) or with hypercalcemia (defined as serum calcium ≥2.56mmol/l) precluding the use of existing vitamin d analogs. the study aims to evaluate the control of shpt, various biochemical parameters of chronic kidney disease-mineral bone disease, left ventricular mass and volumes, vascular calcification and stiffness parameters, handgrip strength and serum albumin with the use of intravenous paricalcitol in patients receiving chronic hemodialysis treatment.

Eligibility criteria:
inclusion criteria: * chronic hemodialysis patients with severe shpt (defined as ipth ≥ 800pg/ml) resistant to rocaltrol or alfacalcidol (defined as ipth not controlled in the range between 2 - 9 times of lab upper limit reference). * chronic hemodialysis patients with severe shpt and at the same time hypercalcemia (defined as serum calcium ≥2.56mmol/l) but still \< 2.8mmol/l precluding the use of rocaltrol or alfacalcidol but still feasible to use paricalcitol. exclusion criteria: * patients with metastatic malignancy, * patients with extremely poor general condition (eg. bedbound) and expected lifespan is below 6 months

Keywords: activated vitamin d treatment
study evaluating the efficacy and safety of remifentanil in a rapid sequence induction for fragile subjects

Conditions: Tachycardia

Summary: the primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.


Eligibility criteria:
inclusion criteria: * patients requiring rapid sequence intubation for whatever reason. this includes the following: a full stomach, obesity, diabetic gastroparesis, gastroesophageal reflux * patient able to give informed consent, and sign the consent. exclusion criteria: * contraindication for the use of any drugs used (regardless of the patient group): a history of serious side effects, allergic reaction * morbid obesity (body mass index \> 40) * emergency situation with unstable hemodynamics, and stabilization is impossible before induction * inclusion in another research project within the past 3 months * the patient is not insured or beneficiary of a health insurance plan (for the french centers) * patient under guardianship of any kind * patient unable to give informed consent * refusal to sign the consent form

Keywords: remifentanil anesthesia induction reactional tachycardia
the canadian cohort obstructive lung disease

Conditions: COPD; Chronic Obstructive Pulmonary Disease

Summary: abstract chronic obstructive pulmonary disease (copd) is the fourth leading cause of death in canada. copd is not just a disease of men, nor is it solely a disease in old age. women have been underrepresented and early disease has not been studied. underdiagnosis of copd remains a significant problem, and it may indicate an unmet healthcare need. this can potentially results not only in a patient been misinformed, but can lead to incorrect management. epidemiological research is needed to develop a framework to combat this major health problem, by better characterization of the population of men and women at risk and patients with early disease, by better understanding which factors modifiable through health interventions are related to health perception (health-related quality of life) and disease evolution. this will be possible through a nationwide study, the canadian cohort obstructive lung disease (cancold), a prospective longitudinal study. the cancold study is built on the current ongoing prevalence nationwide study, the canadian obstructive lung disease "cold" study. the cancold will be the first study to assess prevalence of disease across canada and its consequence in men and women, and to evaluate a conceptual model of disease severity based on patient's health perception (health-related quality of life). ultimately, this project will extend to a longitudinal follow up (3 years or beyond) and will allow to have a better understanding of the lifestyle risk factors, not only smoking but also diet, physical activity, and co morbid conditions. this will be a great asset to shift from management of a single risk factor (tobacco control) to total copd risk management. the results of the study will greatly help to assist decision makers in developing policies to improve the diagnosis, the management of copd and to optimize health care services use.


Eligibility criteria:
inclusion criteria: * all the subjects have taken part in the cold study, a true population based prevalence study. subjects must have an inclusion criteria of 40 years and older to participate in the cold study.

Keywords: chronic obstructive pulmonary disease copd cohort study prospective longitudinal study tissue bank